Bio-Techne/$TECH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bio-Techne
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Ticker
$TECH
Sector
Primary listing
Employees
3,100
Headquarters
Website
Bio-Techne Metrics
BasicAdvanced
$8B
111.43
$0.46
1.39
$0.32
0.62%
Price and volume
Market cap
$8B
Beta
1.39
52-week high
$79.28
52-week low
$46.01
Average daily volume
2.2M
Dividend rate
$0.32
Financial strength
Current ratio
3.459
Quick ratio
2.099
Long term debt to equity
22.408
Total debt to equity
23.142
Dividend payout ratio (TTM)
68.65%
Interest coverage (TTM)
31.17%
Profitability
EBITDA (TTM)
233.003
Gross margin (TTM)
66.50%
Net profit margin (TTM)
6.02%
Operating margin (TTM)
21.75%
Effective tax rate (TTM)
25.45%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
2.92%
Return on equity (TTM)
3.68%
Valuation
Price to earnings (TTM)
111.435
Price to revenue (TTM)
6.62
Price to book
4.14
Price to tangible book (TTM)
13.88
Price to free cash flow (TTM)
31.474
Free cash flow yield (TTM)
3.18%
Free cash flow per share (TTM)
1.629
Dividend yield (TTM)
0.62%
Forward dividend yield
0.62%
Growth
Revenue change (TTM)
5.23%
Earnings per share change (TTM)
-56.19%
3-year revenue growth (CAGR)
3.33%
10-year revenue growth (CAGR)
10.43%
3-year earnings per share growth (CAGR)
-34.80%
10-year earnings per share growth (CAGR)
-4.41%
What the Analysts think about Bio-Techne
Analyst ratings (Buy, Hold, Sell) for Bio-Techne stock.
Bulls say / Bears say
Bio-Techne’s revenue in Q4 FY2025 grew 3.6% year-over-year to $316.96 million, surpassing analysts’ expectations and indicating strong demand within its protein sciences division.
In Q4 FY2025, Bio-Techne reported adjusted EPS of $0.53, beating the consensus estimate of $0.50, which highlights solid operating performance even with ongoing market uncertainties.
Bio-Techne has sold its Exosome Diagnostics unit to Mdxhealth SA for $5 million in stock, allowing it to redirect resources to higher-margin research tools and reagents. Management expects this move will immediately boost operating margins.
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
Bio-Techne Financial Performance
Revenues and expenses
Bio-Techne Earnings Performance
Company profitability
Bio-Techne News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bio-Techne stock?
Bio-Techne (TECH) has a market cap of $8B as of September 14, 2025.
What is the P/E ratio for Bio-Techne stock?
The price to earnings (P/E) ratio for Bio-Techne (TECH) stock is 111.43 as of September 14, 2025.
Does Bio-Techne stock pay dividends?
Yes, the Bio-Techne (TECH) stock pays dividends to shareholders. As of September 14, 2025, the dividend rate is $0.32 and the yield is 0.62%. Bio-Techne has a payout ratio of 68.65% on a trailing twelve-month basis.
When is the next Bio-Techne dividend payment date?
The next Bio-Techne (TECH) dividend payment date is unconfirmed.
What is the beta indicator for Bio-Techne?
Bio-Techne (TECH) has a beta rating of 1.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.